IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.793
EU - Europa 2.173
AS - Asia 584
SA - Sud America 19
AF - Africa 11
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 24.597
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.788
IT - Italia 335
DE - Germania 322
SE - Svezia 318
UA - Ucraina 285
CN - Cina 277
PL - Polonia 234
IE - Irlanda 233
KR - Corea 224
FR - Francia 181
GB - Regno Unito 111
FI - Finlandia 68
RU - Federazione Russa 42
BE - Belgio 18
JP - Giappone 12
VN - Vietnam 12
HK - Hong Kong 11
NL - Olanda 10
AU - Australia 8
CH - Svizzera 8
CL - Cile 8
SG - Singapore 8
KG - Kirghizistan 7
EU - Europa 6
BR - Brasile 5
ET - Etiopia 5
IN - India 5
PK - Pakistan 5
BD - Bangladesh 4
CA - Canada 4
IQ - Iraq 4
AR - Argentina 3
CO - Colombia 3
TR - Turchia 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
DK - Danimarca 2
MN - Mongolia 2
TW - Taiwan 2
ZA - Sudafrica 2
AL - Albania 1
CM - Camerun 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
IL - Israele 1
KZ - Kazakistan 1
MX - Messico 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RO - Romania 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
Totale 24.597
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.680
Wilmington 6.067
Houston 4.704
Fairfield 722
Chandler 606
Ann Arbor 533
Seattle 302
Ashburn 298
Jacksonville 242
Cambridge 231
Kraków 231
Dublin 210
Rome 170
Medford 158
Dearborn 112
New York 108
Beijing 103
Zhengzhou 75
Lawrence 74
San Diego 52
Milan 45
Menlo Park 36
Mülheim 35
Palo Alto 25
Creede 22
Colorado Springs 20
Boardman 18
San Francisco 18
Brussels 17
Falls Church 17
University Park 15
Nanjing 14
London 13
Shanghai 12
Norwalk 11
Cedarhurst 10
Phoenix 10
Dong Ket 9
Hong Kong 9
Guangzhou 8
Redwood City 8
Verona 8
Bari 7
Hefei 7
Helsinki 7
Jinan 7
Mountain View 7
Santa Clara 7
Kunming 6
Magenta 6
Seoul 6
Coventry 5
Los Angeles 5
Manitou Springs 5
Nanchang 5
Palermo 5
Saint Petersburg 5
Fuzhou 4
Hangzhou 4
Kilburn 4
Nürnberg 4
San Mateo 4
Wuhan 4
Adelaide 3
Amsterdam 3
Baghdad 3
Bogotá 3
Detroit 3
Hounslow 3
Indiana 3
Lahore 3
Lausanne 3
Nanning 3
Novokuznetsk 3
Perugia 3
Prescot 3
Redmond 3
St. George 3
São Paulo 3
Tokyo 3
Acton 2
Albano Laziale 2
Belgrade 2
Binasco 2
Brescia 2
Center 2
Central 2
Chengdu 2
Città Sant'Angelo 2
Civitavecchia 2
Council Bluffs 2
Engelhard 2
Fremont 2
Groningen 2
Göttingen 2
Hanoi 2
Hebei 2
Hyderabad 2
Kemerovo 2
Lappeenranta 2
Totale 22.263
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 489
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 452
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 441
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 431
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 426
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 424
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 423
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 420
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 419
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 415
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 413
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 412
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 411
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 411
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 411
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 410
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 409
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 409
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 406
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 406
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 400
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 397
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 393
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 392
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 385
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 375
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 375
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 372
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 370
A case of Italian HIV-2 infection: a genetic analysis 368
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 368
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 366
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 366
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 366
Temporal change in the use of genotypic resistance testing over the years 1999--2003 360
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 359
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 359
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 359
null 357
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 355
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 355
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 353
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 353
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 351
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 350
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 350
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 345
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 344
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 343
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 340
HIV-1 non-B subtypes in Italy: a growing trend 336
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 331
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 329
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 327
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 326
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 318
The V118I mutation as a marker of advanced HIV infection and disease progression 316
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 310
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 302
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 300
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 295
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 280
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 268
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 251
HIV MDR is still a relevant issue despite its dramatic drop over the years 166
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 161
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 94
Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis 91
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 85
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 78
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 73
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 59
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 48
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 42
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 41
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 41
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 40
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 39
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 27
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 23
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 22
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 12
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 11
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 11
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 11
Prevalence of HDV infection in Central Italy has remained stable across the last two decades with dominance of sub-genotypes 1 and characterized by elevated viral replication 10
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 10
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 10
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 10
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 9
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 8
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 7
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 3
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 3
Totale 24.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.537
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.273 0 0 0 0 0 0 0 0 0 0 694 579
2019/20206.249 529 511 418 557 544 705 589 537 544 523 381 411
2020/20213.763 404 430 439 477 340 425 549 355 80 79 128 57
2021/20221.140 60 79 106 67 34 88 48 48 214 83 45 268
2022/20231.510 121 148 114 192 114 291 91 153 123 51 77 35
2023/2024354 59 10 32 21 49 107 25 21 10 20 0 0
Totale 24.898